Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 9, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 7, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$66.49 – $68.45Entry zone — fair-value band

$68.86Published — price the day we called it

$81.72Target — the price the thesis aimed for

$71.00Peak — highest point inside the window, not a realized return

$59.02Window close — end-of-window price, context only

What happened

Partial

Reached 16% of the predicted growth at its peak, without hitting the target.

Peak price

$71.00

peak on July 25, 2025 — not a realized return

Peak gain

+3.1%

peak, from the publication price

Window close

$59.02

end-of-window price, context only

Days to target

—

Window

July 9, 2025 – October 7, 2025

The thesis — published July 9, 2025

Predicted growth

+20%

over the measurement window

Target price

$81.72

the price the thesis aimed for

Entry zone

$66.49 – $68.45

the fair-value band we waited for

Price at publication

$68.86

published July 9, 2025

Confidence

74%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo is strengthening its lead in weight-loss drugs. It has asked European regulators to approve a stronger 7.2 mg Wegovy, and is spending EUR 2.34 billion on a new factory in Rome to avoid shortages. Business strength scores 67 and market mood 84. After weeks of steady trading near its recent average price, prescriptions are rising again, so shares could move from about $69 to $80 within three months.

Primary drivers

Higher-dose Wegovy request protects market lead and could reach more patients.
New EUR 2.34 b Rome plant will boost output and reduce ongoing supply limits.
Ozempic and Wegovy sales may top $45 b by 2027, bringing in strong cash flow.
Price has steadied and upbeat investor mood (84) hints at a coming upswing.

How it played out

NVO: target missed after a 3.1% peak gain

Lyra published NVO on 2025-07-09 at 68.86 with expected growth of 20%. The thesis pointed to a stronger Wegovy dose request in Europe, a EUR 2.34 b Rome factory, possible Ozempic and Wegovy sales above $45 b by 2027, and upbeat market mood at 84. It expected the shares to move toward 81.72 within three months.

Inside the window, NVO peaked at 71 on 2025-07-25, a 3.1% gain. That stayed below the target. The target was never reached. By 2025-10-07, the stock ended at 59.02. The published thesis missed.

What happened during the window

On 2025-07-29, Novo Nordisk cut its 2025 sales growth outlook to 8% to 14% and named Maziar Mike Doustdar as its next CEO. On 2025-08-06, the company reported second-quarter Wegovy sales of 19.53 billion Danish kroner and Ozempic sales of 31.8 billion kroner.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals